Basilea News http://www.basilea.com/ Basilea News en Wed, 23 Jul 2014 10:06:37 +0200 Wed, 23 Jul 2014 10:06:37 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider]]> http://www.basilea.com/News-and-Media/Basilea-to-launch-Zevtera-Mabelio-ceftobiprole-medocaril-in-Europe-through-a-commercial-services-provider/7dcfb10b-c4ef-5a82-8359-f88b1f36cb96 Mon, 21 Jul 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-to-launch-Zevtera-Mabelio-ceftobiprole-medocaril-in-Europe-through-a-commercial-services-provider/7dcfb10b-c4ef-5a82-8359-f88b1f36cb96 <![CDATA[Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections]]> http://www.basilea.com/News-and-Media/Basilea-submits-isavuconazole-European-Marketing-Authorization-Application-for-the-treatment-of-invasive-mold-infections/4829da89-e609-b167-721d-8e68389b5ba6 Thu, 17 Jul 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-submits-isavuconazole-European-Marketing-Authorization-Application-for-the-treatment-of-invasive-mold-infections/4829da89-e609-b167-721d-8e68389b5ba6 <![CDATA[Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-received-QIDP-designation-from-U-S-FDA-for-the-treatment-of-invasive-candidiasis/b845dff4-19aa-8671-ead5-f58974777d68 Wed, 16 Jul 2014 18:07:33 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-received-QIDP-designation-from-U-S-FDA-for-the-treatment-of-invasive-candidiasis/b845dff4-19aa-8671-ead5-f58974777d68 <![CDATA[Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-orphan-drug-designations-in-Europe-for-the-treatment-of-invasive-mold-infections/11f1a7ab-80f8-52db-39a7-c443b9379d8a Mon, 14 Jul 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-orphan-drug-designations-in-Europe-for-the-treatment-of-invasive-mold-infections/11f1a7ab-80f8-52db-39a7-c443b9379d8a <![CDATA[Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis]]> http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-submits-isavuconazole-U-S-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/150fe9ff-7b25-a61a-1bc4-69028145676e Wed, 09 Jul 2014 18:11:23 +0200 http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-submits-isavuconazole-U-S-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/150fe9ff-7b25-a61a-1bc4-69028145676e <![CDATA[Basilea announces start of phase 2a study with oncology drug candidate BAL101553]]> http://www.basilea.com/News-and-Media/Basilea-announces-start-of-phase-2a-study-with-oncology-drug-candidate-BAL101553/22f5b8d9-3820-2869-9f85-f79a5888fbb3 Thu, 26 Jun 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-announces-start-of-phase-2a-study-with-oncology-drug-candidate-BAL101553/22f5b8d9-3820-2869-9f85-f79a5888fbb3 <![CDATA[Basilea provides update on ceftobiprole's U.S. regulatory status]]> http://www.basilea.com/News-and-Media/Basilea-provides-update-on-ceftobiproles-U-S-regulatory-status/50be69bd-f44b-0453-4ae0-7894a0bb3e91 Wed, 25 Jun 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-provides-update-on-ceftobiproles-U-S-regulatory-status/50be69bd-f44b-0453-4ae0-7894a0bb3e91 <![CDATA[Basilea initiates phase 1 combination study with its Gram-negative antibiotic BAL30072 and meropenem]]> http://www.basilea.com/News-and-Media/Basilea-initiates-phase-1-combination-study-with-its-Gram-negative-antibiotic-BAL30072-and-meropenem/b9d97fd2-d4ae-16ad-8a09-1faa146732ba
  • Development program conducted under BARDA agreement
  • ]]>
    Thu, 12 Jun 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-initiates-phase-1-combination-study-with-its-Gram-negative-antibiotic-BAL30072-and-meropenem/b9d97fd2-d4ae-16ad-8a09-1faa146732ba
    <![CDATA[Basilea's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study]]> http://www.basilea.com/News-and-Media/Basileas-oncology-drug-candidate-BAL101553-shows-first-evidence-of-antitumor-activity-in-phase-1-study/453044a8-75a8-a260-3226-8516ba55d9e6
  • Results of recently completed clinical phase 1 study presented at ASCO
  • ]]>
    Mon, 02 Jun 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-oncology-drug-candidate-BAL101553-shows-first-evidence-of-antitumor-activity-in-phase-1-study/453044a8-75a8-a260-3226-8516ba55d9e6
    <![CDATA[Basilea reports additional data on positive isavuconazole phase 3 SECURE study at ECCMID]]> http://www.basilea.com/News-and-Media/Basilea-reports-additional-data-on-positive-isavuconazole-phase-3-SECURE-study-at-ECCMID/8689e8ee-940e-8da2-d7cf-2e25cdd890b0 Wed, 14 May 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-additional-data-on-positive-isavuconazole-phase-3-SECURE-study-at-ECCMID/8689e8ee-940e-8da2-d7cf-2e25cdd890b0